Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Cyanocobalamin Articles

AMD risk reduced by Vit B and folic acid

2 March 2009

Cobalis partners with MDC for PreHistin

26 January 2009

Meda to acquire Recip for $407M+

5 November 2007

Nastech sees 311% income surge in 2005

27 March 2006

Nastech's Nascobal gets FDA approval

7 February 2005

BioGentech changes name to Cobalis

26 July 2004

Nascobal Nasal spray NDA submitted to FDA

5 January 2004

Nascobal use extended, but Schwarz deal ended

8 July 2002

Nasal vitamin B12 drug cleared in Sweden

28 January 2002

Cambridge Licenses Nasal Vitamin B12

12 August 1998

Nastech's Nascobal Cleared In USA

18 November 1996

PROF ALEXANDRE HEADS CPMP MEETING

27 September 1993

Showing 1-12 of 12 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • It's official: "obesity is a disease," says AMA
  • Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
  • Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • It's official: "obesity is a disease," says AMA
  • Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS